Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
Public ClinicalTrials.gov record NCT00615433. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Placebo-and Active Comparator Controlled, Clinical Trial to Study the Safety and Efficacy of Two Doses of Lurasidone HCl in Acutely Psychotic Patients With Schizophrenia.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Lurasidone HCl is a compound developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is more efficacious than placebo. The study will also evaluate the safety and tolerability of lurasidone as compared to placebo.
Study identification
- NCT ID
- NCT00615433
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 478 participants
Conditions and interventions
Conditions
Interventions
- Lurasidone Drug
- Olanzapine Drug
- Placebo comparator Drug
- Lurasidone 40 mg tablets Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2007
- Primary completion
- Nov 30, 2009
- Completion
- Dec 31, 2009
- Last update posted
- Jun 11, 2015
2008 – 2010
United States locations
- U.S. sites
- 25
- U.S. states
- 14
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| K&S Professional Research Services LLC | Little Rock | Arkansas | 72201 | — |
| Woodland International Research Group, LLC | Little Rock | Arkansas | 72211 | — |
| Clinical Pharmacological Studies, Inc. | Cerritos | California | 90703 | — |
| Excell Research | Oceanside | California | 92056 | — |
| University of California at Irvine Medical Center | Orange | California | 92868 | — |
| California Clinical Trials | Paramount | California | 90723 | — |
| CNRI - San Diego, LLC | San Diego | California | 92102 | — |
| UCSD Medical Center | San Diego | California | 92103 | — |
| Collaborative Neuroscience Network Inc. | Torrance | California | 90502 | — |
| Florida Clinical Research Center, LLC | Fruitland Park | Florida | 24731 | — |
| Segal Institute for Clinical Research | North Miami | Florida | 33161 | — |
| Atlanta Center for Medical Research | Atlanta | Georgia | 30308 | — |
| Uptown Research Institute, LLC | Chicago | Illinois | 60640 | — |
| Alexian Brothers Health System | Hoffman Estates | Illinois | 60169 | — |
| Lousiana Clinical Research, LLC | Shreveport | Louisiana | 71104 | — |
| Precise Research Center | Flowood | Mississippi | 39232 | — |
| St. Charles Psychiatric Associates-Midwest Research | Saint Charles | Missouri | 63301 | — |
| St. Louis Clinical Trials | St Louis | Missouri | 63118 | — |
| CRI Worldwide @ Lourdes | Willingboro | New Jersey | 08046 | — |
| Neurobehavioral Research Inc. | Cedarhurst | New York | 11516 | — |
| University of North Carolina at Chapel Hill | Raleigh | North Carolina | 27603 | — |
| Keystone Clinical Studies, LLC | Norristown | Pennsylvania | 19401 | — |
| Vanderbilt Heart and Vascular Institute | Nashville | Tennessee | 37212 | — |
| Community Clinical Research, Inc. | Austin | Texas | 78754 | — |
| Claghorn-Lesem Research Clinic, Inc. | Houston | Texas | 77008 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
Recently updated Schizophrenia trials
Other public records listing Schizophrenia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07615426: A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia Recruiting
- NCT07788755: NEURO-COGS: Neurometabolic Mechanisms of Cognitive Training in Schizophrenia Not yet recruiting
- NCT07783373: Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia Active, not recruiting
- NCT07772349: Enhancing Brain Connectivity in Schizophrenia Through Neuromodulation (Study 3) Not yet recruiting
- NCT07680114: Overnight Thalamic TES-TI to Modulate Sleep Spindles in Individuals With Schizophrenia Spectrum Disorders and Matched Healthy Controls Recruiting
- NCT07734493: A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00615433, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2015 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00615433 live on ClinicalTrials.gov.